Agios Pharmaceuticals Inc (AGIO)
44.78
-0.09
(-0.20%)
USD |
NASDAQ |
Nov 04, 16:00
43.78
-1.00
(-2.23%)
After-Hours: 05:58
Agios Pharmaceuticals Net Income (Quarterly): 947.92M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 947.92M |
| June 30, 2024 | -96.12M |
| March 31, 2024 | -81.55M |
| December 31, 2023 | -95.94M |
| September 30, 2023 | -91.32M |
| June 30, 2023 | -83.81M |
| March 31, 2023 | -81.02M |
| December 31, 2022 | 36.53M |
| September 30, 2022 | -81.75M |
| June 30, 2022 | -91.81M |
| March 31, 2022 | -94.77M |
| December 31, 2021 | -94.63M |
| September 30, 2021 | -88.77M |
| June 30, 2021 | -86.22M |
| March 31, 2021 | 1.874B |
| December 31, 2020 | -97.66M |
| September 30, 2020 | -98.98M |
| June 30, 2020 | -90.48M |
| March 31, 2020 | -40.26M |
| December 31, 2019 | -102.35M |
| September 30, 2019 | -106.17M |
| June 30, 2019 | -109.87M |
| March 31, 2019 | -93.08M |
| December 31, 2018 | -91.79M |
| September 30, 2018 | -94.66M |
| Date | Value |
|---|---|
| June 30, 2018 | -68.74M |
| March 31, 2018 | -90.82M |
| December 31, 2017 | -88.28M |
| September 30, 2017 | -77.14M |
| June 30, 2017 | -83.08M |
| March 31, 2017 | -66.17M |
| December 31, 2016 | -56.49M |
| September 30, 2016 | -62.83M |
| June 30, 2016 | -55.95M |
| March 31, 2016 | -23.20M |
| December 31, 2015 | -40.62M |
| September 30, 2015 | -40.26M |
| June 30, 2015 | -31.90M |
| March 31, 2015 | -4.957M |
| December 31, 2014 | -26.66M |
| September 30, 2014 | 3.704M |
| June 30, 2014 | -18.30M |
| March 31, 2014 | -12.25M |
| December 31, 2013 | -12.38M |
| September 30, 2013 | -11.18M |
| June 30, 2013 | -8.62M |
| March 31, 2013 | -7.228M |
| December 31, 2012 | -5.313M |
| September 30, 2012 | -4.645M |
| June 30, 2012 | -5.513M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-102.35M
Minimum
Dec 2019
1.874B
Maximum
Mar 2021
68.07M
Average
-89.62M
Median
Net Income (Quarterly) Benchmarks
| Pfizer Inc | 4.465B |
| Regeneron Pharmaceuticals Inc | 1.341B |
| Ligand Pharmaceuticals Inc | -51.91M |
| ADMA Biologics Inc | 32.06M |
| AnaptysBio Inc | -46.66M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 8.964M |
| Total Expenses (Quarterly) | 111.78M |
| EPS Diluted (Quarterly) | 16.22 |
| Enterprise Value | 1.549B |
| Gross Profit Margin (Quarterly) | 91.27% |
| Earnings Yield | 25.37% |
| Normalized Earnings Yield | -14.05 |